About SUNREST LIFESCIENCE
SUNREST LIFESCIENCE is a publicly listed company based in Ahmedabad (India) founded in 2018. Healthcare and wellness products are offered via an online platform. The company has 140 employees. Its Indian entity Sunrest Lifescience Limited reported revenue of ₹73.34 Cr. Its focus areas include Traditional Pharmaceuticals.
Company details
Sunrest Lifescience was established in 2018 in Ahmedabad, India, within the healthcare sector. A variety of products focused on hair care, cold relief, pain relief, and related areas is provided. Operations are centered on an online platform that enables browsing and purchasing by customers. The company serves the wellness industry through these direct-to-consumer channels in the Indian market.
- Headquarters Ahmedabad, India
- Employees 140
- Stage Public
- SectorsHealthcare
- Phone•••• ••••
- Website sunrestlifescience.com
- Legal Name Sunrest Lifescience Limited
- Market Cap₹14.38 Cr
SUNREST-SM · NSE
- Share Price₹33.50
0.00% today
- Revenue₹70.83 Cr
FY 2025-26 · +112.0% YoY
- EBITDA₹10.19 Cr
Margin 14.4%
- Net Profit₹1.51 Cr
FY 2025-26 · -24.1% YoY
- P/E (TTM)9.9x
P/B 0.7x
- ROE29.4%
ROCE 28.0%
- Debt / Equity0.80
Interest cover 15.8x
- Employee Count140
Associated legal entities of SUNREST LIFESCIENCE
SUNREST LIFESCIENCE operates through Sunrest Lifescience Limited, a listed company (active). Its filings, financials, charges and directors are on the company page.
| Legal entity | Status | Incorporated | Registered in | Revenue (FY 2026) | Employees | Directors | Company page |
|---|---|---|---|---|---|---|---|
| Sunrest Lifescience Limited Listed CIN L74999GJ2017PLC099606 | Active | 30 Oct 2017 | Ahmadabad City, Gujarat | ₹73.3 Cr | 140 | 8 | View details |
Board of directors of Sunrest Lifescience Limited (SUNREST LIFESCIENCE)
Sunrest Lifescience Limited is the primary company behind SUNREST LIFESCIENCE. The board of Sunrest Lifescience Limited currently have 6 directors; the longest-serving is Amitbhai Shambhulal Thakkar, appointed in 2017. 7 earlier directors have ceased.
| Director | Designation | Appointed | Tenure | Entity |
|---|---|---|---|---|
| Amitbhai Shambhulal Thakkar DIN 07962794 | Whole-time director | 30 Oct 2017 | 8 yrs 11 mo | Sunrest Lifescience Limited |
| Nikhilkumar Yashvntlal Thakkar DIN 07962800 | Managing Director | 30 Oct 2017 | 8 yrs 11 mo | Sunrest Lifescience Limited |
| Bharatkumar Vardhilal Thakkar DIN 08346004 | Director | 15 Mar 2021 | 5 yrs 7 mo | Sunrest Lifescience Limited |
| Bhagyesh Kiritbhai Parekh DIN 07613171 | Director | 31 Jan 2022 | 4 yrs 8 mo | Sunrest Lifescience Limited |
| Juhi Sawajani DIN 09811893 | Director | 01 Mar 2023 | 3 yrs 7 mo | Sunrest Lifescience Limited |
| Avani Ashwinkumar Shah DIN 09608898 | Director | 01 Mar 2023 | 3 yrs 7 mo | Sunrest Lifescience Limited |
IPO & Listings of SUNREST LIFESCIENCE
SUNREST LIFESCIENCE is a publicly listed company on the NSE with ticker symbol SUNREST in India, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
- IPO date20 Nov 2023
- Listed onNSE: SUNREST
- Listed entitySunrest Lifescience Limited
- Exchange sectorHealth technology
- ISININE0PLZ01012
- Share price₹35.35 (-3.81% on the day) · 2026-10-12
- Market capitalisation₹15.2 Cr
- Price to earnings4.1
- EPS (diluted, trailing year)₹8.67
- Volume (last session)4,800
Financials of SUNREST LIFESCIENCE
Exchange-reported figures of Sunrest Lifescience Limited, the listed company behind SUNREST LIFESCIENCE (NSE: SUNREST-SM).
Financial Highlights
FY 2025-26 · ConsolidatedRevenue vs Net Profit ₹ Cr
Margin trends
Financial summary ₹ Cr
| Metrics | FY 2025-26 | FY 2024-25 |
|---|---|---|
| Income statement | ||
| Revenue | 70.83 | 33.41 |
| Revenue growth | +112.0% | - |
| EBITDA | 10.19 | 3.02 |
| EBITDA margin | +14.4% | +9.0% |
| Profit before tax | 10.09 | 2.61 |
| Net profit | 1.51 | 1.99 |
| Net profit margin | +2.1% | +6.0% |
| EPS (₹) | 9.59 | 4.67 |
| Balance sheet | ||
| Total assets | 47.45 | 34.02 |
| Net worth | 20.43 | 16.31 |
| Total debt | 17.46 | 12.06 |
| Cash & bank | 2.76 | 1.74 |
| Net working capital | 38.50 | 28.96 |
| Cash flow | ||
| Cash from operations | (0.05) | 2.92 |
| Cash from investing | (2.91) | (1.15) |
| Cash from financing | 3.99 | (0.33) |
| Metrics | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Income statement | |||||||
| Revenue | 33.26 | 33.12 | 29.48 | 24.64 | 26.89 | 16.95 | 10.95 |
| Revenue growth | +0.4% | +12.4% | +19.6% | -8.4% | +58.6% | +54.8% | - |
| EBITDA | 4.82 | 3.00 | 0.90 | 2.91 | 1.11 | 0.27 | 0.15 |
| EBITDA margin | +14.5% | +9.1% | +3.1% | +11.8% | +4.1% | +1.6% | +1.4% |
| Profit before tax | 4.08 | 2.61 | 0.58 | 2.75 | 1.05 | 0.22 | 0.13 |
| Net profit | 3.09 | 2.00 | 0.22 | 2.05 | 0.76 | 0.17 | 0.03 |
| Net profit margin | +9.3% | +6.0% | +0.8% | +8.3% | +2.8% | +1.0% | +0.3% |
| EPS (₹) | 7.20 | 4.66 | 0.53 | 6.81 | 777.10 | 165.50 | 36.80 |
| Balance sheet | |||||||
| Total assets | 28.81 | 22.69 | 20.35 | 5.26 | 4.31 | 2.61 | 2.40 |
| Net worth | 19.27 | 16.18 | 14.18 | 3.11 | 1.07 | 0.29 | 0.13 |
| Total debt | 9.17 | 6.17 | 6.16 | 2.14 | 3.24 | 2.31 | 2.27 |
| Cash & bank | 0.51 | 0.28 | 0.29 | 0.45 | 0.48 | 0.37 | 0.34 |
| Net working capital | 20.56 | 15.80 | 20.01 | 4.85 | 3.82 | 2.45 | 2.37 |
| Cash flow | |||||||
| Cash from operations | (0.68) | 1.43 | (14.80) | 1.15 | (0.44) | 0.15 | (0.90) |
| Cash from investing | (1.58) | (1.14) | (0.01) | (0.03) | (0.36) | (0.16) | (0.01) |
| Cash from financing | 2.49 | (0.30) | 14.64 | (1.15) | 0.90 | 0.04 | 1.11 |
| Particulars | Sep 2023 | Jun 2023 | Mar 2023 |
|---|---|---|---|
| Revenue | 6.84 | 5.64 | 6.84 |
| Other income | 0.00 | 0.00 | 0.03 |
| Total expenses | 6.19 | 4.63 | 7.16 |
| EBITDA | 0.65 | 1.01 | (0.32) |
| EBITDA margin | +9.5% | +17.9% | -4.7% |
| Depreciation | 0.02 | 0.02 | 0.03 |
| Interest | 0.01 | 0.01 | 0.04 |
| Profit before tax | 0.62 | 0.98 | (0.36) |
| Tax | (0.62) | 0.22 | (0.04) |
Financial Statements
| Particulars | FY 2025-26 | FY 2024-25 |
|---|---|---|
| Revenue | 70.83 | 33.41 |
| Revenue growth | +112.0% | - |
| Other income | 2.51 | 0.00 |
| Total expenses | 60.64 | 30.39 |
| Employee cost | 6.70 | 4.22 |
| EBITDA | 10.19 | 3.02 |
| EBITDA margin | +14.4% | +9.0% |
| Depreciation | 1.19 | 0.10 |
| Interest | 1.42 | 0.31 |
| Profit before tax | 10.09 | 2.61 |
| Tax | 2.11 | 0.61 |
| Net profit | 1.51 | 1.99 |
| Net profit margin | +2.1% | +6.0% |
| EPS (₹) | 9.59 | 4.67 |
| Particulars | FY 2025-26 | FY 2024-25 |
|---|---|---|
| Equity & liabilities | ||
| Share capital | 4.29 | 4.29 |
| Reserves & surplus | 16.14 | 12.02 |
| Shareholders' funds (net worth) | 20.43 | 16.31 |
| Minority interest | 9.20 | 5.32 |
| Secured loans | 14.09 | 9.21 |
| Unsecured loans | 3.37 | 2.85 |
| Total debt | 17.46 | 12.06 |
| Total liabilities | 47.45 | 34.02 |
| Assets | ||
| Gross block | 10.07 | 5.11 |
| Net block | 8.55 | 4.36 |
| Capital work in progress | 0.00 | 0.00 |
| Investments | 0.00 | 0.00 |
| Inventories | 17.06 | 9.62 |
| Sundry debtors | 32.46 | 36.37 |
| Cash & bank balances | 2.76 | 1.74 |
| Loans & advances | 10.18 | 5.86 |
| Total current assets | 62.46 | 53.59 |
| Total current liabilities | 23.96 | 24.63 |
| Net working capital | 38.50 | 28.96 |
| Total assets | 47.45 | 34.02 |
| Particulars | FY 2025-26 | FY 2024-25 |
|---|---|---|
| Opening cash | 1.74 | 0.29 |
| Net cash from operating activities | (0.05) | 2.92 |
| Net cash from investing activities | (2.91) | (1.15) |
| Net cash from financing activities | 3.99 | (0.33) |
| Net change in cash | 1.03 | 1.45 |
| Closing cash | 2.76 | 1.74 |
| Particulars | FY 2025-26 | FY 2024-25 |
|---|---|---|
| Growth | ||
| Sales growth | +112.0% | - |
| EBITDA growth | +237.4% | - |
| PBT growth | +286.6% | +9997.0% |
| Net income growth | -24.1% | - |
| Profitability & leverage | ||
| Net income margin | +11.3% | +6.0% |
| Return on capital employed | +28.0% | +10.2% |
| Return on net worth | +29.4% | +12.3% |
| Debt / equity | 0.80 | 0.74 |
| Long-term debt / equity | 0.48 | 0.35 |
| Interest cover | 15.78 | 10.62 |
| Efficiency & per share | ||
| Fixed asset turnover | 9.33 | 6.54 |
| Inventory turnover | 5.31 | 3.47 |
| Debtors turnover | 2.06 | 0.92 |
| EPS (₹) | 9.59 | 4.67 |
| Dividend per share (₹) | 0.00 | 0.00 |
| Book value per share (₹) | 47.60 | 38.01 |
| Particulars | Sep 2023 | Jun 2023 | Mar 2023 |
|---|---|---|---|
| Revenue | 6.84 | 5.64 | 6.84 |
| Other income | 0.00 | 0.00 | 0.03 |
| Total expenses | 6.19 | 4.63 | 7.16 |
| EBITDA | 0.65 | 1.01 | (0.32) |
| EBITDA margin | +9.5% | +17.9% | -4.7% |
| Depreciation | 0.02 | 0.02 | 0.03 |
| Interest | 0.01 | 0.01 | 0.04 |
| Profit before tax | 0.62 | 0.98 | (0.36) |
| Tax | (0.62) | 0.22 | (0.04) |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Revenue | 33.26 | 33.12 | 29.48 | 24.64 | 26.89 | 16.95 | 10.95 |
| Revenue growth | +0.4% | +12.4% | +19.6% | -8.4% | +58.6% | +54.8% | - |
| Other income | 0.00 | 0.00 | 0.00 | 0.03 | 0.02 | 0.00 | 0.00 |
| Total expenses | 28.44 | 30.12 | 28.58 | 21.73 | 25.78 | 16.68 | 10.80 |
| Employee cost | 0.00 | 4.21 | 3.59 | 2.90 | 2.54 | 2.37 | 2.06 |
| EBITDA | 4.82 | 3.00 | 0.90 | 2.91 | 1.11 | 0.27 | 0.15 |
| EBITDA margin | +14.5% | +9.1% | +3.1% | +11.8% | +4.1% | +1.6% | +1.4% |
| Depreciation | 0.23 | 0.09 | 0.10 | 0.13 | 0.06 | 0.04 | 0.02 |
| Interest | 0.51 | 0.30 | 0.22 | 0.06 | 0.02 | 0.01 | 0.00 |
| Profit before tax | 4.08 | 2.61 | 0.58 | 2.75 | 1.05 | 0.22 | 0.13 |
| Tax | 0.99 | 0.61 | 0.36 | 0.70 | 0.27 | 0.05 | 0.10 |
| Net profit | 3.09 | 2.00 | 0.22 | 2.05 | 0.76 | 0.17 | 0.03 |
| Net profit margin | +9.3% | +6.0% | +0.8% | +8.3% | +2.8% | +1.0% | +0.3% |
| EPS (₹) | 7.20 | 4.66 | 0.53 | 6.81 | 777.10 | 165.50 | 36.80 |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Equity & liabilities | |||||||
| Share capital | 4.29 | 4.29 | 4.29 | 3.00 | 0.01 | 0.01 | 0.01 |
| Reserves & surplus | 14.98 | 11.89 | 9.89 | 0.11 | 1.06 | 0.28 | 0.12 |
| Shareholders' funds (net worth) | 19.27 | 16.18 | 14.18 | 3.11 | 1.07 | 0.29 | 0.13 |
| Secured loans | 5.80 | 3.32 | 2.70 | 0.26 | 0.38 | 0.09 | 0.00 |
| Unsecured loans | 3.37 | 2.85 | 3.46 | 1.88 | 2.86 | 2.22 | 2.27 |
| Total debt | 9.17 | 6.17 | 6.16 | 2.14 | 3.24 | 2.31 | 2.27 |
| Total liabilities | 28.81 | 22.69 | 20.35 | 5.26 | 4.31 | 2.61 | 2.40 |
| Assets | |||||||
| Gross block | 3.08 | 1.50 | 0.53 | 0.53 | 0.51 | 0.19 | 0.06 |
| Net block | 2.67 | 1.33 | 0.26 | 0.35 | 0.46 | 0.15 | 0.03 |
| Capital work in progress | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Investments | 5.52 | 5.52 | 0.02 | 0.02 | 0.00 | 0.00 | 0.00 |
| Inventories | 10.90 | 6.79 | 5.05 | 3.94 | 2.30 | 1.52 | 0.48 |
| Sundry debtors | 18.61 | 19.01 | 15.00 | 10.86 | 9.35 | 7.40 | 5.37 |
| Cash & bank balances | 0.51 | 0.28 | 0.29 | 0.45 | 0.48 | 0.37 | 0.34 |
| Loans & advances | 3.08 | 2.19 | 4.49 | 1.05 | 0.40 | 0.03 | 0.03 |
| Total current assets | 33.10 | 28.27 | 24.83 | 16.30 | 12.53 | 9.32 | 6.22 |
| Total current liabilities | 12.54 | 12.47 | 4.82 | 11.45 | 8.71 | 6.87 | 3.85 |
| Net working capital | 20.56 | 15.80 | 20.01 | 4.85 | 3.82 | 2.45 | 2.37 |
| Total assets | 28.81 | 22.69 | 20.35 | 5.26 | 4.31 | 2.61 | 2.40 |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Opening cash | 0.28 | 0.29 | 0.45 | 0.48 | 0.37 | 0.34 | 0.14 |
| Net cash from operating activities | (0.68) | 1.43 | (14.80) | 1.15 | (0.44) | 0.15 | (0.90) |
| Net cash from investing activities | (1.58) | (1.14) | (0.01) | (0.03) | (0.36) | (0.16) | (0.01) |
| Net cash from financing activities | 2.49 | (0.30) | 14.64 | (1.15) | 0.90 | 0.04 | 1.11 |
| Net change in cash | 0.23 | (0.01) | (0.16) | (0.03) | 0.11 | 0.03 | 0.20 |
| Closing cash | 0.51 | 0.28 | 0.29 | 0.45 | 0.48 | 0.37 | 0.34 |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Growth | |||||||
| Sales growth | +0.4% | +12.4% | +19.6% | -8.4% | +58.6% | +54.8% | - |
| EBITDA growth | +60.7% | +233.3% | -69.1% | +162.2% | +311.1% | +80.0% | - |
| PBT growth | +56.3% | +350.0% | -78.9% | +161.9% | +377.3% | +69.2% | +9997.0% |
| Net income growth | +54.5% | +809.1% | -89.3% | +169.7% | +347.1% | +466.7% | - |
| Revenue CAGR (3Y) | +10.5% | +7.2% | +20.3% | +31.0% | - | - | - |
| EBITDA CAGR (3Y) | +18.3% | +39.3% | +49.4% | +168.7% | - | - | - |
| Profitability & leverage | |||||||
| Net income margin | +9.3% | +6.0% | +0.8% | +8.3% | +2.9% | +1.0% | +0.3% |
| Return on capital employed | - | +13.5% | +6.4% | +58.6% | +30.9% | +9.6% | +5.8% |
| Return on net worth | - | +13.2% | +2.7% | +97.6% | +114.7% | +81.0% | +30.8% |
| Debt / equity | - | 0.41 | 0.48 | 1.29 | 4.09 | 10.93 | 17.46 |
| Long-term debt / equity | - | 0.25 | 0.32 | 1.22 | 3.95 | 10.84 | 17.46 |
| Interest cover | 11.11 | 10.31 | 27.50 | 2.16 | 1.90 | 4.35 | 0.00 |
| Efficiency & per share | |||||||
| Fixed asset turnover | - | 32.63 | 55.62 | 47.38 | 76.83 | 135.60 | 182.50 |
| Inventory turnover | - | 5.59 | 6.56 | 7.90 | 14.08 | 16.95 | 22.81 |
| Debtors turnover | - | 1.95 | 2.28 | 2.44 | 3.21 | 2.65 | 2.04 |
| EPS (₹) | 7.20 | 4.66 | 0.53 | 6.81 | 777.10 | 165.50 | 36.80 |
| Dividend per share (₹) | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Book value per share (₹) | 0.00 | 37.72 | 33.06 | 10.38 | 1,070.40 | 294.90 | 129.40 |
Web traffic of SUNREST LIFESCIENCE
The website of SUNREST LIFESCIENCE (sunrestlifescience.com) receives about 1.8K visits a month.
- Monthly visits1.8K
▼ 17.9% vs previous month
Top companies in Traditional Health & Nutrition
3 companies that operate in the same segment as SUNREST LIFESCIENCE (Traditional Health & Nutrition) in India, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Oral solid drug delivery systems are manufactured and developed. | 1985 | Mumbai, Maharashtra, India | USD 42.49 M | USD 89.42 M | 962 | |
Generic, semi-solid, and liquid dosage forms are manufactured. | 1990 | Bengaluru, Karnataka, India | USD 508.93 M | 5,180 | ||
Specialty generic pharmaceuticals and APIs are manufactured and marketed. | 1983 | Mumbai, Maharashtra, India | USD 6.21 B | 25,870 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Sunrest Lifescience
Complete news archive for SUNREST LIFESCIENCE
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about SUNREST LIFESCIENCE
SUNREST LIFESCIENCE was founded in 2018.
SUNREST LIFESCIENCE is headquartered in Ahmedabad, India. It is registered at Ahmedabad, Gujarat, India.
SUNREST LIFESCIENCE has 140 employees.
The primary company behind SUNREST LIFESCIENCE, Sunrest Lifescience Limited, reported revenue of ₹73.34 Cr for FY 2026, up 112% year on year.
Sunrest Lifescience was established in 2018 in Ahmedabad, India, within the healthcare sector. A variety of products focused on hair care, cold relief, pain relief, and related areas is provided. Operations are centered on an online platform that enables browsing and purchasing by customers. The company serves the wellness industry through these direct-to-consumer channels in the Indian market.
Yes, SUNREST LIFESCIENCE is publicly traded on NSE under the ticker symbol SUNREST.
SUNREST LIFESCIENCE operates through Sunrest Lifescience Limited.
The legal entities of SUNREST LIFESCIENCE currently have 8 directors, including Amitbhai Shambhulal Thakkar, Bhagyesh Kiritbhai Parekh, Nikhilkumar Yashvntlal Thakkar and others.